Please login to the form below

Not currently logged in
Email:
Password:

Zalviso

This page shows the latest Zalviso news and features for those working in and with pharma, biotech and healthcare.

Grunenthal and AcelRx’s Zalviso approved in EU

Grunenthal and AcelRx’s Zalviso approved in EU

Grunenthal and AcelRx’ s Zalviso approved in EU. Provides new treatment for post-operative pain. ... delivery. AcelRx developed Zalviso and entered into a commercial collaboration with Grunenthal at the end of 2013.

Latest news

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Grünenthal's relentless pursuit of relief Grünenthal's relentless pursuit of relief

    It is our passion to help these patients.”. It is also investing in New Technical Entities (NTEs) which include new formulations and devices, acquiring Zalviso, a combination of a medical device

  • Pharma deals in September 2015 Pharma deals in September 2015

    PDL BioPharma is buying out the majority of the expected royalty stream from EU sales of AcelRX's phase III product, Zalviso for $65m. ... Royalty monetisation. 110. AcelRx Pharmaceuticals. PDL BioPharma. Zalviso sub-lingual formulation of sufentanil.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics